Bio-Rad Laboratories (BIO) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Bio-Rad Laboratories published the results on November 4, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Bio-Rad Laboratories reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Bio-Rad's GAAP net income swings with the market value of its stake in Sartorius AG. Q3 2026 included a $588.2 million gain on equity securities; Q3 2025 included a $495.3 million loss.
• Q3 2026 GAAP results include about $77 million of restructuring charges and a $49.8 million impairment of purchased intangibles from the Celsee single-cell business.

Source: Bio-Rad Q3 2026 results, November 4, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Bio-Rad Laboratories splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Bio-Rad Laboratories's Life Science revenue was $255 million in Q3 2026, down 3% from $262 million in Q3 2025, 39% of total revenue.
• Bio-Rad Laboratories's Clinical Diagnostics revenue was $402 million in Q3 2026, up 3% from $391 million in Q3 2025, 61% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Bio-Rad Laboratories said:

“For the full-year 2026, the Company continues to expect non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent.”

“Forecasted non-GAAP operating margin excludes 83 basis points related to amortization of purchased intangibles.”

Source: Bio-Rad Q3 2026 release, Nov 4, 2026.

This is the company's own guidance as of Nov 4, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the BIO forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Net sales and GAAP diluted EPS, each as first reported in that quarter's release. The large GAAP EPS swings come mostly from changes in the fair market value of Bio-Rad's Sartorius AG shares.

We do not hold a confirmed date for Bio-Rad Laboratories's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 4, 2026

Bio-Rad Laboratories reports two segments. In Q3 2026 Clinical Diagnostics had net sales of $401.8 million, up 2.7%, and Life Science $254.6 million, down 2.8%, for a total of $656.4 million against $653.0 million. On a currency-neutral basis total sales rose 0.7 percent. (Bio-Rad Q3 2026 release (Form 8-K, Exhibit 99.1), Nov 4, 2026; Bio-Rad Form 10-Q, quarter ended September 30, 2026, Nov 4, 2026)

Bio-Rad's Clinical Diagnostics segment sells diagnostic test systems, test kits, informatics and specialized quality controls to clinical laboratories, supporting more than 300 clinical diagnostic tests. Bio-Rad said its currency-neutral growth of 2.8 percent in the quarter was primarily driven by quality systems and diabetes products. (Bio-Rad Form 10-K, year ended December 31, 2025, Feb 13, 2026; Bio-Rad Q3 2026 release (Form 8-K, Exhibit 99.1), Nov 4, 2026)

Life Science sells instruments, reagents and consumables used to separate, purify and quantify cells, proteins and nucleic acids, to research labs and biopharmaceutical manufacturers. Its 2.4 percent currency-neutral decline came from lower process chromatography sales and ongoing challenges in the academic research market. Excluding process chromatography, Life Science revenue grew 2.5% currency-neutral, and the Droplet Digital PCR franchise grew 7%, with instrument revenue up 20%+. (Bio-Rad Form 10-K, year ended December 31, 2025, Feb 13, 2026; Bio-Rad Q3 2026 release (Form 8-K, Exhibit 99.1), Nov 4, 2026; Bio-Rad Q3 2026 supplemental earnings presentation (Form 8-K, Exhibit 99.2), Nov 4, 2026)

In Q3 2026 the Americas were 45% of Bio-Rad Laboratories' revenue, EMEA 34% and Asia Pacific 21%. For the full year 2025, about 40% of net sales came from the U.S. and about 60% from international locations, with Europe the largest international region. (Bio-Rad Q3 2026 supplemental earnings presentation (Form 8-K, Exhibit 99.2), Nov 4, 2026; Bio-Rad Form 10-K, year ended December 31, 2025, Feb 13, 2026)

Bio-Rad Laboratories' GAAP diluted EPS was $17.02 in Q3 2026, against a loss of $12.70 a year earlier, and non-GAAP diluted EPS was $2.65, against $2.26. The gap comes mainly from Bio-Rad's stake in Sartorius AG, which it marks to market: a $588.2 million gain in the quarter, against a $495.3 million loss a year earlier. At September 30, 2026 Bio-Rad owned approximately 38% of Sartorius's ordinary shares and 28% of its preference shares. (Bio-Rad Q3 2026 release (Form 8-K, Exhibit 99.1), Nov 4, 2026; Bio-Rad Form 10-Q, quarter ended September 30, 2026, Nov 4, 2026)

Bio-Rad's GAAP operating result was a loss of $49.7 million because of $77.2 million of restructuring costs and a $49.8 million impairment. The impairment wrote the Celsee single-cell technology, acquired in 2020, down to zero after Bio-Rad cut research and marketing investment in those products. Under its July 2026 restructuring plan Bio-Rad expects total pre-tax costs of approximately $80 million to $90 million. Non-GAAP operating margin was 12.8%, against 11.8%. (Bio-Rad Q3 2026 release (Form 8-K, Exhibit 99.1), Nov 4, 2026; Bio-Rad Form 10-Q, quarter ended September 30, 2026, Nov 4, 2026)

The GAAP effective tax rate was 14.9 percent, against 20.7 percent, and the non-GAAP rate 21.4 percent, against 26.7 percent, which Bio-Rad put down to the geographical mix of earnings. Diluted weighted average shares were 26,945 thousand. In the first nine months of 2026 Bio-Rad repurchased 286,685 Class A shares for $79.3 million, and $206.0 million remained under its 2023 program. (Bio-Rad Q3 2026 release (Form 8-K, Exhibit 99.1), Nov 4, 2026; Bio-Rad Form 10-Q, quarter ended September 30, 2026, Nov 4, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Bio-Rad Laboratories gives full-year guidance on a non-GAAP, currency-neutral basis. On November 4, 2026 it kept its 2026 outlook for revenue of a decline of approximately 3.0 percent to growth of approximately 0.5 percent and a non-GAAP operating margin of approximately 10.0 to 12.0 percent. Its supplemental presentation added free cash flow of $290M to $340M and a non-GAAP gross margin of 53.0% to 54.0%. (Bio-Rad Q3 2026 release (Form 8-K, Exhibit 99.1), Nov 4, 2026; Bio-Rad Q3 2026 supplemental earnings presentation (Form 8-K, Exhibit 99.2), Nov 4, 2026)

A consensus figure is the average of the models published by the analysts who cover Bio-Rad Laboratories, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Bio-Rad Laboratories's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning BIO is on is BIO a buy or a sell?, what analysts expect next is on the BIO forecast, and what the company does is on the Bio-Rad Laboratories (BIO) stock page.

Every number on this page can be traced to a document Bio-Rad Laboratories published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.